{"pmid":32489653,"pmcid":"PMC7242011","title":"Interrelationship Between Coronavirus Infection and Liver Disease.","text":["Interrelationship Between Coronavirus Infection and Liver Disease.","Clin Liver Dis (Hoboken)","Schaefer, Esperance A K","Arvind, Ashwini","Bloom, Patricia P","Chung, Raymond T","32489653"],"journal":"Clin Liver Dis (Hoboken)","authors":["Schaefer, Esperance A K","Arvind, Ashwini","Bloom, Patricia P","Chung, Raymond T"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489653","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cld.967","topics":["Diagnosis","Treatment","Mechanism"],"weight":1,"_version_":1668623433709125632,"score":9.490897,"similar":[{"pmid":32251539,"title":"COVID-19 and liver disease.","text":["COVID-19 and liver disease.","Since December 2019, patients with unexplained pneumonia have been found in Wuhan, Hubei Province, China, which was caused by a novel coronavirus that had not been previously identified (1). Tentatively defined as 2019 novel coronavirus (2019-nCoV), the pathogen has now been named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (2), while the disease termed Coronavirus Disease 2019 (COVID-19).","Liver Int","Sun, Jian","Aghemo, Alessio","Forner, Alejandro","Valenti, Luca","32251539"],"abstract":["Since December 2019, patients with unexplained pneumonia have been found in Wuhan, Hubei Province, China, which was caused by a novel coronavirus that had not been previously identified (1). Tentatively defined as 2019 novel coronavirus (2019-nCoV), the pathogen has now been named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (2), while the disease termed Coronavirus Disease 2019 (COVID-19)."],"journal":"Liver Int","authors":["Sun, Jian","Aghemo, Alessio","Forner, Alejandro","Valenti, Luca"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251539","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1111/liv.14470","keywords":["covid-19","sars-cov-2","coronavirus","infection","liver disease"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Treatment","Prevention"],"weight":1,"_version_":1666138490931249152,"score":43.58158},{"pmid":32274341,"pmcid":"PMC7132021","title":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","text":["Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19.","J Clin Transl Hepatol","Li, Jie","Fan, Jian-Gao","32274341"],"abstract":["An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19."],"journal":"J Clin Transl Hepatol","authors":["Li, Jie","Fan, Jian-Gao"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274341","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.14218/JCTH.2020.00019","keywords":["covid-19","clinical characteristics","liver injury","mechanism","sars-cov-2"],"locations":["Wuhan","China","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1666138491651620864,"score":41.537354}]}